Related Experiment Video
Updated: Jul 1, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
How CBX proteins regulate normal and leukemic blood cells
Anne P de Groot1,2, Gerald de Haan1,2,3
1European Research Institute for Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), The Netherlands.
Insights
Chromobox (CBX) proteins within Polycomb Repressive Complex 1 (PRC1) regulate hematopoietic stem cell (HSC) self-renewal. Different CBX proteins influence HSC fate, aging, and leukemia, offering therapeutic targets.
Area of Science:
- Hematology
- Epigenetics
- Molecular Biology
Background:
- Hematopoietic stem cell (HSC) self-renewal is crucial for blood formation and is regulated by epigenetic mechanisms.
- Polycomb Repressive Complex 1 (PRC1) plays a key role in repressing differentiation genes, maintaining HSC function.
- The specific chromobox (CBX) protein subunit of PRC1 influences HSC fate decisions.
Purpose of the Study:
- To review the diverse roles of chromobox (CBX) proteins in regulating hematopoietic stem cell (HSC) fate.
- To explore how CBX proteins contribute to age-related changes and oncogenic transformations in HSCs.
- To discuss therapeutic strategies targeting CBX proteins in leukemia.
Main Methods:
- Literature review of studies on PRC1, CBX proteins, and HSC biology.
- Analysis of the epigenetic and non-epigenetic functions of CBX proteins.
- Examination of the impact of CBX proteins on HSC self-renewal, aging, and leukemogenesis.
Main Results:
- Different CBX proteins (CBX2, CBX4, CBX6, CBX7, CBX8) within PRC1 lead to distinct HSC fate outcomes.
- CBX proteins influence age-related HSC alterations and promote oncogenic pathways.
- CBX2, CBX7, and CBX8 are implicated in enhancing leukemia progression.
- Both canonical epigenetic and alternative non-epigenetic interactions of CBX proteins are relevant.
Conclusions:
- CBX proteins are critical regulators of HSC fate, with specific subunits impacting self-renewal, aging, and disease.
- Targeting the epigenetic functions of oncogenic CBX proteins presents a promising therapeutic avenue for leukemia.
- Further research is needed to elucidate the non-epigenetic roles of cytoplasmic CBX proteins in blood cell development and disease.
Abstract:
Hematopoietic stem cell (HSC) fate decisions are dictated by epigenetic landscapes. The Polycomb Repressive Complex 1 (PRC1) represses genes that induce differentiation, thereby maintaining HSC self-renewal. Depending on which chromobox (CBX) protein (CBX2, CBX4, CBX6, CBX7, or CBX8) is part of the PRC1 complex, HSC fate decisions differ. Here, we review how this occurs. We describe how CBX proteins dictate age-related changes in HSCs and stimulate oncogenic HSC fate decisions, either as canonical PRC1 members or by alternative interactions, including non-epigenetic regulation. CBX2, CBX7, and CBX8 enhance leukemia progression. To target, reprogram, and kill leukemic cells, we suggest and describe multiple therapeutic strategies to interfere with the epigenetic functions of oncogenic CBX proteins. Future studies should clarify to what extent the non-epigenetic function of cytoplasmic CBX proteins is important for normal, aged, and leukemic blood cells.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Negative Regulator Molecules
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

